PFG Advisors Purchases 50 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

PFG Advisors boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,465 shares of the company’s stock after purchasing an additional 50 shares during the quarter. PFG Advisors’ holdings in IDEXX Laboratories were worth $3,086,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IDXX. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $25,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $31,000. Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $37,000. Finally, Kestra Investment Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $38,000. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IDXX has been the subject of a number of recent analyst reports. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $412.40 on Thursday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $550.24. The business has a 50-day simple moving average of $438.09 and a two-hundred day simple moving average of $448.02. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $33.54 billion, a PE ratio of 38.65, a PEG ratio of 3.41 and a beta of 1.39.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.